SCHEMBL1287474

SCHEMBL1287474

[CH2]c1ccccc1Cc1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CALM1 P0DP23 1/20 0.52
HTR2A P28223 1/20 0.50
BCL2 P10415 1/20 0.48
BCL2L1 Q07817 1/20 0.48
ALOX5 P09917 1/20 0.42
HPGD P15428 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
KEAP1 Q14145 1/20 0.40
CYP3A4 P08684 1/20 0.39
ALOX15 P16050 1/20 0.39
HIF1A Q16665 1/20 0.39
HSD17B10 Q99714 1/20 0.39
DRD2 P14416 1/20 0.39
DRD1 P21728 1/20 0.39
DRD4 P21917 1/20 0.39
DRD5 P21918 1/20 0.39
HRH1 P35367 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2223002 0.84 HSPA5 (0.46) CALM1HTR2AMEN1KMT2AKEAP1
SCHEMBL28025384 0.82 TP53 (0.46) HTR2ASMN1; SMN2KEAP1
SCHEMBL5852567 0.82 CYP3A4 (0.52) HTR2AKEAP1CYP3A4L3MBTL1
SCHEMBL972711 0.81 CALM1 (0.69) CALM1HTR2ABCL2BCL2L1ALOX5
SCHEMBL10653799 0.81 HTR2A (0.42) CALM1HTR2ABCL2BCL2L1ALOX5
SCHEMBL2028062 0.81 BCL2 (0.50) HTR2ABCL2BCL2L1ALOX5KEAP1
SCHEMBL1287637 0.78 HTR1A (0.48) HTR2AHPGDSMN1; SMN2ALOX15HSD17B10
SCHEMBL27713690 0.78 TACR1 (0.35) BCL2BCL2L1CYP3A4
SCHEMBL3246541 0.76 TAAR1 (0.45) HPGDKMT2A
SCHEMBL10799851 0.75 CALM1 (0.52) CALM1HTR2ABCL2BCL2L1ALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 208 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240002344-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION FIBROGEN, INC. 2024-01-04 US claimed
EP-4204400-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION Fibrogen, Inc. (US) 2023-07-05 EP claimed
US-20040116410-A1 Diazepinones as antiviral agents CHO HIDETSURA (JP) 2004-06-17 US claimed
US-5885548-A Multiply substituted DTPA derivatives and their metal complexes, and their metal complexes, pharmaceutical agents that contain these complexes, their use in diagnosis and therapy, as well as process for the production of pharmaceutical agents SCHERING AKTIENGESELLSCHAFT (DE) 1999-03-23 US claimed
US-5746995-A DTPA derivatives substituted in a novel way, their metal complexes, and their use in diagnosis and therapy SCHERING AKTIENGESELLSCHAFT (DE) 1998-05-05 US claimed
US-20240208992-A1 MACROCYCLES AS CFTR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2024-06-27 US disclosed
WO-2024048076-A1 APPARATUS FOR PRODUCING FIBER-REINFORCED COMPOSITE SHEET AND METHOD FOR PRODUCING FIBER-REINFORCED COMPOSITE SHEET DIC株式会社 2024-03-07 WO disclosed
WO-2023163144-A9 OPTICAL LAMINATE FOR OLED DISPLAY DEVICE 日東電工株式会社 2024-02-01 WO disclosed
WO-2024010041-A1 ADHESIVE AND ADHESIVE SHEET 日東電工株式会社 2024-01-11 WO disclosed
WO-2024010042-A1 PRESSURE-SENSITIVE ADHESIVE AND PRESSURE-SENSITIVE ADHESIVE SHEET 日東電工株式会社 2024-01-11 WO disclosed
US-20240002344-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION FIBROGEN, INC. 2024-01-04 US disclosed
WO-2024004861-A1 ACTIVE ENERGY RAY-CURABLE COMPOSITION, AND CURED PRODUCT THEREOF DIC株式会社 2024-01-04 WO disclosed
US-5610294-A VIRAL TREATMENT THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1997-03-11 US disclosed
WO-1996000241-A1 PROCESS FOR THE PREPARATION OF PEPTIDE TRISULFIDES PHARMACIA & UPJOHN AB (SE) 1996-01-04 WO disclosed
EP-0662965-A1 1,2-DISUBSTITUTED ETHYL AMIDES AS INHIBITORS OF ACAT SCHERING CORPORATION (US) 1995-07-19 EP disclosed
WO-1994006784-A1 1,2-DISUBSTITUTED ETHYL AMIDES AS INHIBITORS OF ACAT SCHERING CORPORATION (US) 1994-03-31 WO disclosed
US-4939186-A Aliphatic or aromatic alkene hydrocarbons or oxy compounds polycarbonateester copolymers, blends GENERAL ELECTRIC COMPANY (US) 1990-07-03 US disclosed
US-4920091-A CONTAINING SALICYLIC ACID DERIVATIVE AS ELECTRON ACCEPTING COLOR DEVELOPER; STABLE IMAGES FUJI PHOTO FILM CO., LTD. (JP) 1990-04-24 US disclosed
US-4847377-A ANTIHYPERPROLIFERATIVE SKIN DISEASES SCHERING CORPORATION (US) 1989-07-11 US disclosed
US-4816458-A TOPICAL ADMINISTERING SCHERING CORPORATION (US) 1989-03-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240208992-A1 MACROCYCLES AS CFTR MODULATORS CFTR, PKD1, ARRB1 CALM1 2526/4885HTR2A 1200/4885BCL2 3433/4885
US-20240002344-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION KDM5C, KDM5B, KDM5A CALM1 1625/4885HTR2A 3818/4885BCL2 2886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.